1542. MR-proADM Biomarker Predicts COVID-19 Clinical Outcomes: a US-based Cohort Study

ABSTRACT: Abstract

Background

Mid-regional proadrenomedullin (MR-proADM) is a biomarker released following endothelial damage. Our study aimed to investigate baseline MR-proADM as a predictor of a wider range of clinical outcomes of varying severity in patients admitted with COVID-19 from a US-based multicenter trial. Outcomes Within 28 days Stratified by Binary MR-proADM (Cutoff 0.87 Nmol/L), Number of Events (percentage)

SUBMITTER:  

PROVIDER: S-EPMC9751617 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature